CIRCLE-seq: A highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets

被引:0
|
作者
Tsai S.Q. [1 ,2 ,3 ,4 ,6 ]
Nguyen N.T. [1 ,2 ,3 ]
Malagon-Lopez J. [1 ,2 ,3 ,4 ,5 ]
Topkar V.V. [1 ,2 ,3 ]
Aryee M.J. [1 ,2 ,3 ,4 ,5 ]
Joung J.K. [1 ,2 ,3 ,4 ]
机构
[1] Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA
[2] Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA
[3] Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, MA
[4] Department of Pathology, Harvard Medical School, Boston, MA
[5] Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA
[6] Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN
关键词
D O I
10.1038/nmeth.4278
中图分类号
学科分类号
摘要
Sensitive detection of off-target effects is important for translating CRISPR-Cas9 nucleases into human therapeutics. In vitro biochemical methods for finding off-targets offer the potential advantages of greater reproducibility and scalability while avoiding limitations associated with strategies that require the culture and manipulation of living cells. Here we describe circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq), a highly sensitive, sequencing-efficient in vitro screening strategy that outperforms existing cell-based or biochemical approaches for identifying CRISPR-Cas9 genome-wide off-target mutations. In contrast to previously described in vitro methods, we show that CIRCLE-seq can be practiced using widely accessible next-generation sequencing technology and does not require reference genome sequences. Importantly, CIRCLE-seq can be used to identify off-target mutations associated with cell-type-specific single-nucleotide polymorphisms, demonstrating the feasibility and importance of generating personalized specificity profiles. CIRCLE-seq provides an accessible, rapid, and comprehensive method for identifying genome-wide off-target mutations of CRISPR-Cas9. © 2017 Nature America, Inc. All rights reserved.
引用
收藏
页码:607 / 614
页数:7
相关论文
共 50 条
  • [41] High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
    Kleinstiver, Benjamin P.
    Pattanayak, Vikram
    Prew, Michelle S.
    Tsai, Shengdar Q.
    Nguyen, Nhu T.
    Zheng, Zongli
    Joung, J. Keith
    NATURE, 2016, 529 (7587) : 490 - +
  • [42] Abnoba-Seq: a highly sensitive and unbiased in vitro assay to profile CRISPR/Cas nuclease off-target activity
    Haas, S. A.
    Hildenbeutel, M.
    Cathomen, T.
    HUMAN GENE THERAPY, 2017, 28 (12) : A13 - A13
  • [43] Large-scale genome-wide CHANGE-seq profiling of CRISPR-Cas9 therapeutic targets reveals genetic and epigenetic determinants of activity
    Lazzarotto, Cicera R.
    Malinin, Nikolay
    Katta, Varun
    Li, Yichao
    Cheng, Yong
    Tsai, Shengdar Q.
    TRANSGENIC RESEARCH, 2020, 29 (04) : 473 - 473
  • [44] A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer
    Ipsen, Malene Blond
    Sorensen, Ea Marie Givskov
    Thomsen, Emil Aagaard
    Weiss, Simone
    Haldrup, Jakob
    Dalby, Anders
    Palmfeldt, Johan
    Bross, Peter
    Rasmussen, Martin
    Fredsoe, Jacob
    Klingenberg, Soren
    Jochumsen, Mads R.
    Bouchelouche, Kirsten
    Ulhoi, Benedicte Parm
    Borre, Michael
    Mikkelsen, Jacob Giehm
    Sorensen, Karina Dalsgaard
    ONCOGENE, 2022, 41 (37) : 4271 - 4281
  • [45] A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer
    Malene Blond Ipsen
    Ea Marie Givskov Sørensen
    Emil Aagaard Thomsen
    Simone Weiss
    Jakob Haldrup
    Anders Dalby
    Johan Palmfeldt
    Peter Bross
    Martin Rasmussen
    Jacob Fredsøe
    Søren Klingenberg
    Mads R. Jochumsen
    Kirsten Bouchelouche
    Benedicte Parm Ulhøi
    Michael Borre
    Jacob Giehm Mikkelsen
    Karina Dalsgaard Sørensen
    Oncogene, 2022, 41 : 4271 - 4281
  • [46] Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma
    Liu, Jiye
    Xing, Lijie
    Hideshima, Teru
    Kurata, Keiji
    Samur, Mehmet K.
    Morelli, Eugenio
    Wen, Kenneth
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    BLOOD, 2022, 140
  • [47] Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
    Kiessling, Michael K.
    Schuierer, Sven
    Stertz, Silke
    Beibel, Martin
    Bergling, Sebastian
    Knehr, Judith
    Carbone, Walter
    de Valliere, Cheryl
    Tchinda, Joelle
    Bouwmeester, Tewis
    Seuwen, Klaus
    Rogler, Gerhard
    Roma, Guglielmo
    BMC GENOMICS, 2016, 17
  • [48] Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
    Michael K. Kiessling
    Sven Schuierer
    Silke Stertz
    Martin Beibel
    Sebastian Bergling
    Judith Knehr
    Walter Carbone
    Cheryl de Vallière
    Joelle Tchinda
    Tewis Bouwmeester
    Klaus Seuwen
    Gerhard Rogler
    Guglielmo Roma
    BMC Genomics, 17
  • [49] Genome-wide CRISPR-Cas9 screens reveal modulators of temozolomide sensitivity in glioblastoma
    MacLeod, Graham
    Rajakulendran, Nishani
    Hart, Traver
    Yu, Helen
    Dirks, Peter B.
    Angers, Stephane
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10)
  • [50] Nomination of Genome-Wide CRISPR-Cas9 Cleavage Activity Using rhAmp Technology
    Turk, Rolf
    Kinney, Kyle
    Zhang, He
    Osborne, Thomas
    Wang, David
    Rettig, Garrett
    MOLECULAR THERAPY, 2024, 32 (04) : 790 - 790